

APPENDIX B

3/5/1

DIALOG(R)File 9:Business & Industry(R) Jul
(c) 1998 Resp. DB Svcs. All rts. reserv.

01908105 (USE FORMAT 7 OR 9 FOR FULLTEXT)

First Monoclonal Antibody OKed For Cancer In USA

(FDA panel has recommended approval of a monoclonal antibody developed by IDEC Pharmaceuticals and Genentech for the treatment of follicular B-cell non-Hodgkin's lymphoma)

Marketletter, p N/A

August 04, 1997

DOCUMENT TYPE: Newsletter ISSN: 0951-3175 (United Kingdom)

LANGUAGE: English RECORD TYPE: Fulltext

WORD COUNT: 838

ABSTRACT:

FDA panel has recommended approval of a monoclonal antibody developed by IDEC Pharmaceuticals and Genentech for the treatment of follicular B-cell non-Hodgkin's lymphoma. Rituxan, which could be the first monoclonal antibody to be approved for the treatment of cancer, has less serious side effects and takes less time to administer.

COMPANY NAMES: GENENTECH INC (ROCHE HOLDING AG); IDEC PHARMACEUTICALS CORP

INDUSTRY NAMES: Pharmaceutical

PRODUCT NAMES: Biologics for human use NEC (283657)

CONCEPT TERMS: All product and service information; Product development

GEOGRAPHIC NAMES: North America (NOAX); United States (USA)

3/5/2

DIALOG(R)File 9:Business & Industry(R) Jul
(c) 1998 Resp. DB Svcs. All rts. reserv.

01726189

Monoclonal Antibodies: Using New Techniques to Reduce Development Time
(Companies are working to improve production of monoclonal antibodies to commercial levels)

Genetic Engineering News, v 17, n 2, p 13+

January 15, 1997

DOCUMENT TYPE: Journal; Industry Overview ISSN: 0270-6377 (United States)

LANGUAGE: English RECORD TYPE: Abstract

ABSTRACT:

Almost 80 monoclonal antibodies (Mabs) are now in clinical trials--nearly half of all biologics now in clinical trial. Mabs, which require repeated dosing, and progress in new production technology is beginning to make commercial production possible.

In 1995, for example, the market for parenteral-grade antibodies was relatively small. For the 11,902 kidney transplants done in that year, according to the National Kidney Foundation, only 6-12 kg of Mab would have been adequate to counter rejection in every kidney transplanted. Recent studies on the use of Mab in treatment of breast or lung cancer, for which the American Cancer Society estimates about 180,000 new cases/yr, suggest that this market would need only a couple of kg/yr. To gain a 30% market share of Mabs used in therapeutic settings, a company would have to produce 30-60 kg of purified bulk product/yr.

A table shows the effect of Mab expression on number and volume of bioreactor runs required to produce 60 k/yr.

The article discusses the technological issues in bulk production of Mabs and notes progress being made by companies such as Lonza (Portsmouth, NH, and Slough, UK) and IDEC Pharmaceuticals (San Diego, CA).

COMPANY NAMES: IDEC PHARMACEUTICALS CORP ; LONZA INC
(ALUSUISSE-LONZA
HOLDING AG

INDUSTRY NAMES: Pharmaceutical

PRODUCT NAMES: Biologics for human use NEC (283657)

CONCEPT TERMS: All market information; All product and service information
; Market size; Product development

GEOGRAPHIC NAMES: North America (NOAX); United States (USA)

3/5/3

DIALOG(R)File 9:Business & Industry(R) Jul
(c) 1998 Resp. DB Svcs. All rts. reserv.

01420385 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Genentech/IDEC collaborate on lymphoma drug

(IDEC Pharmaceuticals Corp and Genentech expand collaborative pact to include clinical development of IDEC-Y2B8)

Pharmaceutical Business News, n 262, p 28

February 28, 1996

DOCUMENT TYPE: Newsletter ISSN: 0956-0661 (United Kingdom)

LANGUAGE: English RECORD TYPE: Fulltext

WORD COUNT: 235

TEXT:

IDEC Pharmaceuticals Corp and Genentech, Inc have expanded their collaborative agreement to include the clinical development and commercialisation of IDEC-Y2B8, IDEC's radioconjugate for the treatment of B-cell lymphomas. IDEC expects to begin Phase II clinical testing of IDEC-Y2B8 during 1996.

As part of the initial March 1995 agreement with IDEC, Genentech retained an option to IDEC-Y2B8 through the end of Phase II clinical testing. Genentech has opted to participate in the Phase II trial and will pay \$1.5 million to IDEC as an option fee and reimburse up to \$1.5 million of trial costs. Further details of the expanded collaboration are under discussion including funding to conduct pivotal clinical testing and support product registration.

IDEC and Genentech's first collaborative agreement, focused on the clinical development and commercialisation of IDEC-C2B8. Currently in Phase III clinical testing, IDEC-C2B8 is a genetically engineered monoclonal antibody for treatment of B-cell lymphomas. The addition of IDEC-Y2B8 to the collaboration should expand the range of lymphomas which may be treated with these immunotherapies, potentially including bulkier, later stage and more refractory tumours.

IDEC-Y2B8 is designed to destroy B-cell tumours by delivering a targeted, radiopharmaceutical agent to the cancer cells. The product consists of an anti-CD20 antibody coupled to the high-energy radioisotope, yttrium90. IDEC believes IDEC-Y2B8 may allow safer, more effective radiation therapy than is possible with current, external radiation treatments. Additionally, IDEC-Y2B8 allows radiation therapy to be conducted in outpatient settings.

Copyright 1996 FT Information Online Ltd., newsletters

COMPANY NAMES: GENENTECH INC (ROCHE HOLDING AG); IDEC
PHARMACEUTICALS
CORP

INDUSTRY NAMES: Pharmaceutical

PRODUCT NAMES: Antineoplastics and cancer therapy drugs (283419)

CONCEPT TERMS: All company; All product and service information; Joint
venture; Product development

GEOGRAPHIC NAMES: North America (NOAX); United States (USA)

DIALOG(R)File 9:Business & Industry(R) Jul
(c) 1998 Resp. DB Svcs. All rts. reserv.

01418925 (USE FORMAT 7 OR 9 FOR FULLTEXT)

IDEC, Genentech Lymphoma Alliance

(IDEC Pharmaceuticals, Genentech expand alliance to include clinical development of IDEC-Y2B8, IDEC's radioconjugate for treatment of B cell lymphoma)

Marketletter, p N/A

February 26, 1996

DOCUMENT TYPE: Newsletter ISSN: 0951-3175 (United Kingdom)

LANGUAGE: English RECORD TYPE: Fulltext

WORD COUNT: 58

TEXT:

IDEC Pharmaceuticals and Genentech have expanded their collaborative alliance to include the clinical development of IDEC-Y2B8, IDEC's radioconjugate for the treatment of B cell lymphoma. The two companies have been working together since March 1995 on IDEC-C2B8, a monoclonal antibody in Phase III trials for the same indication. Phase II trials of the radioconjugate should begin soon.

Copyright 1996 Marketletter Publications Ltd.

COMPANY NAMES: GENENTECH INC; IDEC PHARMACEUTICALS CORP

INDUSTRY NAMES: Pharmaceutical

PRODUCT NAMES: Antineoplastics and cancer therapy drugs (283419)

CONCEPT TERMS: All company; All product and service information; Joint venture; Product development

GEOGRAPHIC NAMES: North America (NOAX); United States (USA)

3/5/5

DIALOG(R)File 9:Business & Industry(R) Jul

(c) 1998 Resp. DB Svcs. All rts. reserv.

01377642 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Industry News (Patents and Technology) Allowance Received for Antigen that Elicits T-Cell Responses

(DEC Pharmaceuticals announces receipt of notice of allowance for US patent for methods to induce specific cell-mediated responses in humans and animals; develops non-toxic antigen formulation, called AF, to be known as Provax)

Vaccine Weekly, p N/A

January 08, 1996

DOCUMENT TYPE: Newsletter ISSN: 1065-6073 (United States)

LANGUAGE: English RECORD TYPE: Fulltext
WORD COUNT: 452

ABSTRACT:

IDEC Pharmaceuticals Corp (San Diego, CA) announced the receipt of a notice of allowance for a US patent covering methods to safely induce specific cell-mediated responses in humans and animals. The company also announced the publication of a study showing that mice immunized with tumor antigens formulated using these methods mounted antigen-specific cellular responses against the corresponding tumors, resulting in tumor regression. The study conducted in collaboration with investigators at the US National Cancer Institute (NCI) was published in the December 20, 1995 , issue of the Journal of the National Cancer Institute. IDEC has developed a non-toxic antigen formulation, called AF, that when mixed with soluble antigens, safely induces specific CTL responses, as well as strong antibody responses. IDEC announced that it will begin using the trade name, Provax, for this antigen formulation previously known as AF. Nabil Hanna, Ph.D., senior vice president of research and preclinical development at IDEC, said, preliminary studies indicate that AF can be safely administered by injection to human subjects, and said the company believes the technology may find wide application in the development of new vaccine-based immunotherapies. Provax will be made available through licenses and collaborations to interested corporate partners for development of immunotherapeutic vaccines. Full text discusses trial results of AF, now to be called Provax.

COMPANY NAMES: IDEC PHARMACEUTICALS CORP

INDUSTRY NAMES: Pharmaceutical

PRODUCT NAMES: Antineoplastics and cancer therapy drugs (283419);
Vaccines, toxoids and antigens for human use (283638)

CONCEPT TERMS: All intellectual property; Patents

GEOGRAPHIC NAMES: North America (NOAX); United States (USA)

3/5/6

DIALOG(R)File 9:Business & Industry(R) Jul
(c) 1998 Resp. DB Svcs. All rts. reserv.

01333809 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Industry News (Clinical Trials) Company Reports on Lymphoma Trial Combining
IDEC-C2B8 with Chemotherapy

(IDEC Pharmaceuticals is developing IDEC-C2B8 and CHOP chemotherapy as
treatments for low-grade, B-cell lymphoma)

Cancer Biotechnology Weekly, p N/A

November 13, 1995

DOCUMENT TYPE: Newsletter ISSN: 0896-7385 (United States)

LANGUAGE: English RECORD TYPE: Fulltext

WORD COUNT: 828

ABSTRACT:

IDEC Pharmaceuticals Corporation, San Diego, California, released preliminary results of a Phase II combination trial of IDEC-C2B8 and CHOP chemotherapy in patients with low-grade, B-cell lymphoma. Overall response rate for the 16 evaluable patients to-date was 100 percent, and all responses are ongoing from five to 18 months. Of the 16 patients, 11 achieved a complete response and five achieved a partial response. Moreover, all patients who, prior to treatment, expressed a cellular marker called bcl-2 that is associated with the development of multi-drug resistance, became negative for that marker by completion of therapy. Adverse events attributed by the researchers to IDEC-C2B8 consisted primarily of mild, flu-like symptoms, usually associated with the first infusion. The researchers observed no antibody responses against IDEC-C2B8 nor unusual toxicities for the combination of CHOP and antibody therapy. "Based on this trial and our previous studies of IDEC-C2B8 as a single agent, we believe this product offers potential for treating low-grade lymphoma both on its own and as part of a combination approach to therapy. Because IDEC-C2B8's mode of action is separate from that of conventional, chemotherapeutic drugs, it is not subject to the same mechanisms of cellular resistance that make conventional chemotherapy less effective over time," said William H. Rastetter, president and chief executive officer of IDEC. For patients with low-grade lymphoma, bcl-2 status post-therapy may have prognostic value and may also serve as a marker to monitor minimal, residual disease. Research has also shown that patients treated with conventional chemotherapy alone do not become bcl-2-negative. IDEC is currently developing IDEC-C2B8, in collaboration with Genentech, Inc. as a single agent for the treatment of relapsed low grade and follicular non-Hodgkin's lymphomas (NHL). The company began a pivotal, Phase III trial of IDEC-C2B8 for this indication in April 1995, which is being conducted at over 30 clinical sites and leading cancer centers in the United States and Canada. B-cell lymphomas are cancers that affect the body's antibody - producing cells. Low-grade and follicular NHL currently afflict roughly 150,000 Americans, with about 20,000 new diagnoses made each year. IDEC's anti-lymphoma antibody, IDEC-C2B8, targets an antigen (CD20) that is expressed on the surface of mature B cells and on B-cell tumors, but not on B-cell precursors or on plasma cells. IDEC-C2B8 works by binding to its target antigen and recruiting host defenses to attack and kill both malignant and normal B cells. Following treatment, the normal B cells regenerate from stem cells within months. IDEC-C2B8 does not damage bone marrow and when used as a single-agent therapy, IDEC-C2B8 is administered on an outpatient basis over

22 days, versus the four- to eight-month course required for most conventional chemotherapies.

COMPANY NAMES: GENENTECH INC (ROCHE HOLDING AG); IDEC PHARMACEUTICALS

CORP

INDUSTRY NAMES: Pharmaceutical

PRODUCT NAMES: Antineoplastics and cancer therapy drugs (283419)

CONCEPT TERMS: All company; All product and service information; Joint venture; Product development

GEOGRAPHIC NAMES: North America (NOAX); United States (USA)

3/5/7

DIALOG(R)File 9:Business & Industry(R) Jul

(c) 1998 Resp. DB Svcs. All rts. reserv.

01207199 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Genentech Inc

(Genentech will jointly develop and commercialize Idec Pharmaceutical's Idec-C28 monoclonal antibody)

R&D Directions, v 1, n 2, p 32

June 1995

DOCUMENT TYPE: Journal (United States)

LANGUAGE: English RECORD TYPE: Fulltext

WORD COUNT: 195

TEXT:

Genentech Inc. entered a \$57 million clinical development and commercialization arrangement with Idec Pharmaceuticals Corp., a biotechnology company. The companies will jointly develop and commercialize Idec's Idec-C2BB monoclonal antibody as a treatment of non-Hodgkin's B-cell lymphoma.

Under terms of the arrangement, Genentech is responsible for an initial payment of \$9 million in equity investment and licensing fees, \$17.5 million in additional equity purchases before U.S. approval of Idec-C2B8, and up to \$30.5 million in milestone and option payments. Idec and Genentech will sell Idec-C2B8 in the United States and Canada with Idec receiving a share of profits. Genentech has commercialization rights to Idec-C2B8 throughout the rest of the world, excluding Asia. Idec is entitled to royalty payments from sales outside the United States and Canada.

The compound is expected to enter Phase III clinical studies by mid-1995 .

Unlike chemotherapy and high-dose radiation, Idec-C2B8 kills malignant and normal B cells with minimal toxicity and does not damage bone marrow. Granulocytes, platelets, and red blood cells remain normal during treatment, and normal B cells regenerate within months. In addition, Genentech can expand the accord to include two Idec radioconjugates: Idec-Y2B8 and Idec-In2B8, both treatments of B-cell lymphoma.

Copyright 1995 Engel Publishing Partners

COMPANY NAMES: GENENTECH GMBH (ROCHE HOLDING AG); IDEC PHARMACEUTICALS

CORP

INDUSTRY NAMES: Pharmaceutical

PRODUCT NAMES: Antineoplastics and cancer therapy drugs (283419)

CONCEPT TERMS: All company; All intellectual property; All market information; All product and service information; Capital expenditures; Joint venture; Patent license; Product development; Test marketing

BRAND NAMES: Idec-C2B8

GEOGRAPHIC NAMES: North America (NOAX); United States (USA)

3/5/8

DIALOG(R)File 9:Business & Industry(R) Jul

(c) 1998 Resp. DB Svcs. All rts. reserv.

01181275 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Collaborations...Idec Pharmaceuticals Corp

(Idec Pharmaceuticals Corp enters development arrangement with Genentech Inc to develop Idec's Idec-C2B8 monoclonal antibody)

Med Ad News, v 14, n 5, p 70

May 1995

DOCUMENT TYPE: Journal; News Brief ISSN: 0745-0907 (United States)

LANGUAGE: English RECORD TYPE: Fulltext

WORD COUNT: 193

TEXT:

Idec Pharmaceuticals Corp. entered a \$57 million clinical development and commercialization arrangement with Genentech Inc. The companies will jointly develop and commercialize Idec's Idec-C2B8 monoclonal antibody as a treatment of non-Hodgkin's B-cell lymphoma. The compound is expected to enter Phase III clinical studies by mid-1995. Unlike chemotherapy and high-dose radiation, Idec-C2B8 kills malignant and normal B cells with minimal toxicity and does not damage bone marrow. Granulocytes, platelets, and red blood cells remain normal during treatment, and normal B cells regenerate within months. Genentech has an option to expand the accord to

include two Idec radioconjugates: Idec-Y2B8 and Idec-In2B8, both treatments of B-cell lymphomas. Under the terms of the arrangement, Genentech is responsible for an initial payment of \$9 million in equity investment and licensing fees, \$17.5 million in additional equity purchases before U.S approval of Idec-C2B8, and up to \$30.5 million in milestone and option payments. Idec and Genentech will both sell Idec-C2B8 in the United States and Canada, with Idec receiving a share of profits. Genentech has commercialization rights throughout the rest of the world, excluding Asia. Idec is entitled to royalty payments from sales outside the United States and Canada.

Copyright 1995 Engel Publishing Partners

COMPANY NAMES: GENENTECH INC (ROCHE HOLDING AG); IDEC PHARMACEUTICALS CORP

INDUSTRY NAMES: Pharmaceutical

PRODUCT NAMES: Antineoplastics and cancer therapy drugs (283419)

CONCEPT TERMS: All company; All intellectual property; All product and service information; Capital expenditures; Joint venture; Patent license; Product development

GEOGRAPHIC NAMES: North America (NOAX); United States (USA)

3/5/9

DIALOG(R)File 9:Business & Industry(R) Jul

(c) 1998 Resp. DB Svcs. All rts. reserv.

01155004 (USE FORMAT 7 OR 9 FOR FULLTEXT)

IDEC/Genentech's Anti-CD20 Antibody In Phase III Soon?

(Genentech and IDEC Pharmaceuticals to jointly collaborate on developing IDEC's monoclonal antibody targeting CD20)

Marketletter, p N/A

March 27, 1995

DOCUMENT TYPE: Newsletter ISSN: 0951-3175 (United Kingdom)

LANGUAGE: English RECORD TYPE: Fulltext

WORD COUNT: 355

TEXT:

Genentech and IDEC Pharmaceuticals have signed an agreement to collaborate on the development of IDEC's monoclonal antibody targeting CD20, a potential treatment for non-Hodgkin's B cell lymphoma. IDEC-C2B8 is expected to enter Phase III clinical trials by mid-1995 , according to Genentech.

As part of the agreement, Genentech also gains the option to extend the collaboration to include two radioconjugates for the treatment of B-cell lymphomas, IDEC-Y2B8 and IDEC-In2B8, which are currently in Phase I/II testing. The two companies may also develop IDEC-C2B8 for other B-cell cancers, including chronic lymphocytic leukemia. Genentech has also licensed from IDEC a technology base relating to a Chinese hamster ovary cell gene expression system which has the potential to reduce the time and cost of product development.

Phase II results of a trial with IDEC-C2B8 have demonstrated that the antibody initiate tumor shrinkage in 22 out of 34 patients with relapsed low-grade or follicular non-Hodgkin's B-cell lymphoma (November 4, 1994). Of the patients who showed shrinkage, three exhibited a complete response, 13 had a partial response (tumor shrinkage >50%) and six had minor responses (shrinkage >25% but <50%). Response durations ranged from 4.4 to 9.2 months. The results showed a response rate similar to that produced by single-agent chemotherapy, said IDEC, but with few of the toxicities associated with these treatments.

Under the terms of the agreement, Genentech will provide \$9 million upfront in preferred equity investments and licensing fees, \$17.5 million in additional equity funding prior to US approval, and up to \$30.5 million in milestone and option payments. The potential value of the deal is \$57 million, according to Genentech. The two companies will copromote IDEC-C2B8 in the USA and Canada. Genentech gains marketing rights throughout the rest of the world except Asia, where it has certain option rights. IDEC will receive royalties on sales outside North America.

IDEC-C2B8 joins two other potential cancer treatments in Phase III clinical trials at Genentech - its anti-HER2 antibody for breast cancer and Actimmune (interferon gamma-1b) for renal cell carcinoma. Also, the company is looking at ras oncogene inhibitors (see adjacent story), anti-vascular endothelial growth factor and thrombopoietin in preclinical testing.

Copyright 1995 Marketletter Publications Ltd.

COMPANY NAMES: GENENTECH INC (ROCHE HOLDING AG); IDEC
PHARMACEUTICALS
CORP

INDUSTRY NAMES: Pharmaceutical

PRODUCT NAMES: Antineoplastics and cancer therapy drugs (283419);
Vaccines, toxoids and antigens for human use (283638)

CONCEPT TERMS: All company; All product and service information; Joint
venture; Product development

GEOGRAPHIC NAMES: North America (NOAX); United States (USA)

3/5/10

DIALOG(R)File 9:Business & Industry(R) Jul
(c) 1998 Resp. DB Svcs. All rts. reserv.

01154578

In Brief: Genentech

(Genentech will work with Idec Pharmaceuticals to develop and market the latter's CD20 monoclonal antibody)

European Chemical News, v 63, n 1660, p 22

March 27, 1995

DOCUMENT TYPE: Journal; News Brief ISSN: 0014-2875 (United Kingdom)

LANGUAGE: English RECORD TYPE: Abstract

ABSTRACT:

Genentech entered a multimillion dollar pact with Idec Pharmaceuticals to develop and market the latter's CD20 monoclonal antibody for the treatment of non-Hodgkin's B-cell lymphomas. The drug, called Idec-C2B8, is scheduled to enter Phase III clinical trials by mid-1995 . Genentech will provide \$9 mil in preferred equity investments and licensing fees, \$17.5 mil in equity funding and up to \$30.5 mil in milestone and options payments.

COMPANY NAMES: GENENTECH INC (ROCHE HOLDING AG); IDEC PHARMACEUTICALS

CORP

INDUSTRY NAMES: Pharmaceutical

PRODUCT NAMES: Antineoplastics and cancer therapy drugs (283419)

CONCEPT TERMS: All company; All product and service information; Joint venture; Product development

GEOGRAPHIC NAMES: North America (NOAX); United States (USA)

3/5/11

DIALOG(R)File 9:Business & Industry(R) Jul
(c) 1998 Resp. DB Svcs. All rts. reserv.

01070611 (USE FORMAT 7 OR 9 FOR FULLTEXT)

IDEC-C2B8 Shows Promise In Phase II

(IDEC's IDEC-C2B8 anticancer antibody reduced tumor size in 22 out of 34 patients with non-Hodgkin's B-cell lymphoma)

Marketletter, p N/A

November 07, 1994

DOCUMENT TYPE: Newsletter ISSN: 0951-3175 (United Kingdom)
LANGUAGE: English RECORD TYPE: Fulltext
WORD COUNT: 178

TEXT:

Phase II results of a trial with IDEC's anticancer antibody , IDEC-C2B8, has demonstrated tumor shrinkage in 22 out of 34 patients with relapsed low-grade or follicular non-Hodgkin's B-cell lymphoma, according to a presentation at the Ninth Annual Scientific Meeting on the Biological Therapy of Cancer.

Of the 22 patients who showed shrinkage, three exhibited a complete response to therapy, 13 a partial response (tumor shrinkage greater than 50%) and six minor responses (shrinkage greater than 25% but less than 50%). All but three of the patients exhibiting complete or partial response remain in remission, said the company, with response durations to date ranging from 4.4 to over 9.2 months.

The results showed a response rate similar to that produced by single-agent chemotherapy, but with none of the toxicities associated with those treatments, said Antonio Grillo-Lopez, company vice president of medical and regulatory affairs.

William Rastetter, IDEC president, said that the product could offer an effective and safe outpatient therapy and a meeting with the US Food and Drug Administration is planned to design pivotal trials to examine this.

Copyright 1994 Marketletter Publications Ltd.

COMPANY NAMES: IDEC CORP

INDUSTRY NAMES: Pharmaceutical

PRODUCT NAMES: Antineoplastics and cancer therapy drugs (283419)

CONCEPT TERMS: All product and service information; Product development

GEOGRAPHIC NAMES: North America (NOAX); United States (USA)

3/5/12

DIALOG(R)File 9:Business & Industry(R) Jul

(c) 1998 Resp. DB Svcs. All rts. reserv.

01065164 (USE FORMAT 7 OR 9 FOR FULLTEXT)

IDEC To Enter Further Trials

(IDEC seeks Phase III tests of C2B8 monoclonal antibody for B-cell lymphoma; tests likely to start in 1995)

Marketletter, p N/A

October 24, 1994

DOCUMENT TYPE: Newsletter; News Brief ISSN: 0951-3175 (United Kingdom)

LANGUAGE: English RECORD TYPE: Fulltext

WORD COUNT: 60

TEXT:

After successful early trials, IDEC says it plans to hold talks with the US Food and Drug Administration soon regarding Phase III clinical testing of its C2B8 monoclonal antibody treatment for B-cell lymphoma, according to company president William Rastetter and chief financial officer David Ludvigson, who added that they expect Phase III tests will be conducted early next year.

Copyright 1994 Marketletter Publications Ltd.

COMPANY NAMES: IDEC PHARMACEUTICALS CORP

INDUSTRY NAMES: Pharmaceutical

PRODUCT NAMES: Antineoplastics and cancer therapy drugs (283419);

Biologics for human use NEC (283657)

CONCEPT TERMS: All product and service information; Product development

GEOGRAPHIC NAMES: North America (NOAX); United States (USA)

3/5/13

DIALOG(R)File 9:Business & Industry(R) Jul

(c) 1998 Resp. DB Svcs. All rts. reserv.

01062628

IDEC Sees Meeting Forecasts for Quarter; Test of Drug Expected
(IDEC Pharmaceuticals to enter Phase 3 clinical testing of monoclonal antibody treatment for lymphoma)

Wall Street Journal , v CCXXIV, n 75, p B9F

October 17, 1994

DOCUMENT TYPE: Business Newspaper ISSN: 0099-9660 (United States)

LANGUAGE: English RECORD TYPE: Abstract

ABSTRACT:

IDEC Pharmaceuticals Corp is expected to enter the Phase 3 clinical tests of C2B8 monoclonal antibody treatment for B-cell lymphoma in early-1995 . R&D outlays for the firm are expected at about US\$5.3 mil/quarter in the foreseeable future. IDEC reported cash and securities of US\$17.7 mil at 6/30/94. It will hold talks with the Federal Drug Administration (FDA) concerning the testing.

COMPANY NAMES: IDEC PHARMACEUTICALS CORP

INDUSTRY NAMES: Pharmaceutical

PRODUCT NAMES: Antineoplastics and cancer therapy drugs (283419)

CONCEPT TERMS: All product and service information; Product development;
R&D expenditures

GEOGRAPHIC NAMES: North America (NOAX); United States (USA)